Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pooled Antipsychotic Data Will Be Mined For Early Response Signals

Executive Summary

A consortium of international drug companies hopes to leverage their pooled schizophrenia data into a means of determining which patient subgroups are most likely to respond to treatment during clinical trials.

You may also be interested in...



GSK Spins Out Pain Assets, Raises $35.4m

UK-based Convergence's lead asset starts Phase II in neuropathic pain

Antipsychotic Drugs Are Medco's New Personalized Medicine Target

Medco will launch a research project in November that aims to validate a biomarker that may improve the cost effectiveness of atypical antipsychotics. The pharmacy benefit manager announced a research collaboration with development-stage genetic test developer SureGene on Aug. 24

Fanapt Pharmacogenetic Data Suggestive But Not Conclusive, FDA Finds

FDA's review of the pharmacogenetic data in Vanda's NDA for Fanapt (iloperidone) suggests that sponsors should be prepared for the agency to require significant clinical evaluation before including pharmacogenetic criteria in labeling

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel